Anika Therapeutics, Inc. (ANIK) Price / FCF

Anika Therapeutics, Inc. Price-FCF Ratio

The price-to-free-cash-flow (P/FCF) ratio tells you how many dollars investors pay for each dollar of cash a company generates after paying for its capital spending. It is market capitalization divided by free cash flow over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher ratio means investors are paying more for each dollar of free cash flow; a negative ratio means the company spent more cash than it generated over those quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

• Anika Therapeutics, Inc. price-fcf ratio for the quarter ending 2026-06-30 was 348.15, a change of 632.47 year-over-year.
• Anika Therapeutics, Inc. price-fcf ratio for the quarter ending 2026-03-31 was 186.02, a change of 250.32 year-over-year.
• Anika Therapeutics, Inc. price-fcf ratio for the quarter ending 2025-12-31 was 30.63, a change of 132.43 year-over-year.
• Anika Therapeutics, Inc. price-fcf ratio for the quarter ending 2025-09-30 was 208.86, a change of 658.05 year-over-year.
• Anika Therapeutics, Inc. price-fcf ratio for fiscal 2026 was 348.15.
• Anika Therapeutics, Inc. price-fcf ratio for fiscal 2025 was 30.63, a change of 132.43 from fiscal 2024.
• Anika Therapeutics, Inc. price-fcf ratio for fiscal 2024 was -101.8, a change of -55.75 from fiscal 2023.
• Anika Therapeutics, Inc. price-fcf ratio for fiscal 2023 was -46.04, a change of 94.65 from fiscal 2022.